Brutalist Biotech

• Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data (1h)
• Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B (2h)
• Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win (6h)
• PureTech shows durability of pulmonary fibrosis candidate deupirfenidone (21h)
• Schrödinger lays off 60 staffers amid ‘uncertain times and challenging economic conditions’ (22h)
• BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government (1d)
• Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential (1d)
• SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies (1d)
• RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies (1d)
• Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck (1d)
• Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease (1d)
• Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win (1d)
• Prime Medicines CEO exits as biotech shelves sole clinical gene therapy, lays off staff (1d)
• Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2 (2d)
• Regeneron’s $256M bid wins 23andMe bankruptcy auction (2d)
• 'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts (2d)
• Pfizer-backed CellCentric secures $120M for further myeloma trials (2d)
• Armata links bacteria-killing virus to clinical responses in phase 2 trial (2d)
• Applied's rare disease drug suffers another phase 3 failure months after FDA rejection (2d)
• Apnimed eyes sleep apnea drug submission after positive phase 3 results (4d)

• FDA sets stricter approval standards for COVID vaccines (22h)
• Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (23h)
• Pfizer buys into PD-1/VEGF competition with 3SBio deal (1d)
• Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot (2d)
• Novavax’s COVID vaccine gets FDA approval, but with limits (2d)
• Regeneron wins bid to buy 23andMe out of bankruptcy (2d)
• Judge shuts down drugmakers’ 340B rebate plans, for now (2d)
• FDA OKs first blood test to aid Alzheimer’s diagnosis (2d)
• How regulatory convergence is raising the bar for sterile drug safety—and how West leads the way (2d)
• From insight to impact: How eCOAs strengthen trial data quality (2d)
• Bridging the data gaps that impact retail and specialty-lite success (2d)
• BioMarin to buy rare disease drugmaker Inozyme for $270M (5d)
• Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (5d)
• Novo CEO to depart as obesity drugmaker’s challenges rise (5d)
• A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases (5d)
• FDA delays approval decision for Biohaven rare disease drug (6d)

• Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong (16m)
• Researchers reveal mixed results from vaccine for cocaine addiction (56m)
• Shutting down a dementia care startup (59m)
• Genentech expands partnership with molecular glue biotech Orionis (3h)
• How PureTech’s lung fibrosis drug stacks up against the competition (4h)
• Altos Labs buys anti-aging startup Dorian Therapeutics (6h)
• Reproductive health biotech ReproNovo closes $65M Series A (6h)
• UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates (8h)
• Vinay Prasad makes first major imprint on FDA with new vaccine policy (18h)
• FDA adcomm votes against new indication for Genentech's cancer drug (18h)
• CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer (20h)
• RFK Jr. spars with senators over HHS budget and research cuts (20h)
• Future Covid vaccine approvals may narrow to older adults, high-risk people (23h)
• Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets (1d)
• SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff (1d)
• Trump administration reveals 'most favored nation' drug price country targets (1d)
• Weight loss startup Calibrate replaces CEO in leadership shakeup (1d)
• Optura raises $6.5M to help evaluate healthcare AI programs (1d)
• At-home screening startup Reperio Health raises $14M (1d)
• Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent (1d)

• In Biotech’s ‘Moribund’ Market, What Does It Take to Survive? (57m)
• Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn (1h)
• Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space (1h)
• RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing (2h)
• Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion (2h)
• Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan (4h)
• The Top 5 Most Active Corporate VCs in Pharma (9h)
• Evolving Market Pressures Force Biopharma Companies to Cut Assets Early (10h)
• FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad (19h)
• New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs (23h)
• CRISPR Success in Single Baby Highlights Rare Disease 'Crisis' (23h)
• Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market (1d)
• Prime Cuts 25% of Staff, Deprioritizes CGD Programs (1d)
• Understanding What Trump’s MFN Executive Order Can and Can’t Do (1d)
• CRISPR Expands Focus, Pays Up To $95M in Sirius' siRNA Pact (1d)
• Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza (1d)
• Makary Backs Psychedelics for Neuropsych, Promises Speedy Review (1d)
• Pfizer Puts $6B on the Line For 3SBio's PD-1/VEGF Antibody (1d)
• The Memory Gap: How Forgotten Diseases Are Making a Dangerous Comeback (2d)
• Deep Dive: Checkpoint Inhibitors at a Crossroads (2d)

Bio IT World

• Innovative Practices Winner: Chromatography Data Management (9h)
• Regeneron Acquires 23andMe for $256 Million (1d)
• Trends from the Trenches: Data, Discovery, Politics (6d)
• Sweden's PROMISE Initiative: Bridging Research and Healthcare Through Multi-Omics (1w)
• CFDE Unites Data Enthusiasts During Hackathon before Kick-Off of Bio-IT World Conference (1w)
• MiLabs Launches Platforma: Bridging the Gap Between Biology and Bioinformatics (2w)
• First-of-its-Kind AI Tool Reveals the ‘Social Network’ of Cancer Cells (2w)
• Illumina, Ovation Release GLP-1 Patient Dataset (2w)
• Illumina, Tempus AI Collaboration, CN Bio, Pharmaron Partnership, More (3w)
• PacBio Licenses New Methylation Tech for HiFi Sequencing, Will Deliver to Revio, Vega Systems (3w)
• Follow the Money: Cancer Platform Expansion, Wearable Device for Metabolic Health, More (3w)
• Advancing Precision Medicine with Ethical AI and Standardized Data (4w)
• Tech Veteran Chris Dwan Challenges Life Sciences to Build Infrastructure, Businesses Strategically (4w)
• AI in Drug Development: Promise and Pitfalls (4w)
• Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research (1mo)
• AI Continues to Make Strides on Therapeutics and Research Progress (1mo)
• Derek Lowe on AI in Drug Discovery: Between Hype and Hope (1mo)
• Large Language Model Predicts, as Well as Explains, Molecular Properties (1mo)
• AI Struggles and Opportunities in Life Sciences and Healthcare (1mo)
• Researchers Transform Gut Bacteria into ‘Little Pharmacists’ (1mo)

• Will AGI cure cancer? Author Karen Hao on OpenAI’s promises and track record (31m)
• Investors unfazed by FDA’s Covid vaccine framework (1h)
• With the U.S. gone, WHO nations will increase contributions (1h)
• We’re reading about Trump’s drug-pricing plan, a Moderna change of plans, and more (1h)
• Risk scores accurately predicted heart attacks, study finds. With CT scans, they did even better (5h)
• Biden’s diagnosis highlights little-noticed rise in late-stage prostate cancers (6h)
• How photography helped heal a couple in the aftermath of cancer (6h)
• A husband and wife photographed each other during her cancer journey. Here is what they learned (6h)
• Proposed changes to the Public Service Loan Forgiveness program would be devastating to new physicians (6h)
• Three big ideas to actually ‘Make America Healthy Again’ (6h)
• Blunt Rochester presses RFK Jr. on CDC acting director (16h)
• New FDA framework on Covid vaccines leaves pediatricians confused and concerned (16h)
• RFK Jr. meets with health tech startups, most backed by Andreessen Horowitz (17h)
• Maryland governor signs law to expand powers of the state’s prescription drug affordability board (20h)
• Regeneron makes another deal — This one about AI (20h)
• Mental health apps can boost outcomes and lower costs, study finds (21h)
• Access to diabetes care in lower-income countries still lags for children, despite pharma efforts (23h)
• FDA will limit Covid vaccines to people over 65 or at high risk of serious illness, leaders say (23h)
• Trump administration lays out more details of plan to lower drug prices (1d)
• We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more (1d)

• Valinor Discovery Launches to Simulate Drug Efficacy in Virtual Patients (2d)
• Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery (2d)
• Kvantify Taps Gefion AI Supercomputer to Scale Quantum Chemistry Simulations for Drug Discovery (2d)
• Eligo Bioscience Gets $5M Grant to Advance Gene-Editing Skin Therapy Using Bacteria (2d)
• Absci Doses First Participants in Phase 1 Trial of AI-Designed Antibody for IBD (2d)
• Medable Updates Digital Platform With Oncology-Focused Tools Ahead of ASCO 2025 (2d)
• Researchers Use Terahertz Imaging for First-Ever 3D View of Cochlea Without Surgery (2d)
• CRISPR Therapy Saves Infant With Rare Genetic Disorder (2d)
• Oracle Rebuilds Its EHR Infrastructure to Support AI-Native Workflows (2d)
• Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery (2d)

• Layoffs in the US: what is going on with genomics companies? (58m)
• Gene therapy for skin diseases: A field still finding its footing (6h)
• Seven lung cancer companies advancing new treatments in 2025 (1d)
• Will Europe become the new home for US researchers affected by policy shifts? (2d)
• Nine promising small molecule drug discovery companies to look out for in 2025 (5d)
• Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells (5d)
• Expert tips to choose the right CDMO for your biotech company (6d)
• The stem cell race for Parkinson’s disease: Recent studies show significant promise (1w)
• Nine biotech companies in Montreal to keep an eye on in 2025 (1w)
• Cracking the code: Delivering biotherapeutics successfully across EMEA (1w)
• Pharma giants pull back on AAV research: what’s next for the gene therapy space? (1w)
• The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 (2w)
• Inside Flagship Pioneering’s strategy: How this VC turns ideas into biotech giants (2w)
• Unlocking immunity: the power of TLR agonists (2w)
• Top biotech deals of April 2025 (2w)

• Potential ALS Mitochondrial Target Identified with CRISPR, scRNA-seq (2h)
• Oligo Factory’s Low-Scale Synthesis Expands Access to Small, GMP-Ready Custom Nucleotides (2h)
• Rapid Method for Cell Density Measurement Could Help Predict Tumor Response to Treatment (16h)
• ASGCT 2025: Gates Foundation “Doubling Down” on HIV Cure (1d)
• Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox (1d)
• Donor Heart Damage From Cold Storage May Be Prevented by Diuretic (1d)
• The News from New Orleans: GEN‘s Takeaways from ASGCT (1d)
• CellProthera Selects CELLforCURE by SEQENS for Phase III GMP Manufacturing (1d)
• Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits (1d)
• Why the Right Launch Strategy Can Get Biopharma from Clinical Breakthroughs to Commercial Blockbusters (1d)
• Biopharma is Mentally Ready, Yet Unprepared for AI Integration (1d)
• Regeneron to Acquire 23andMe with Winning $256M Bid (2d)
• 10x Settles Bruker, Vizgen Patent Lawsuits (2d)
• EvoCAST Harnesses CRISPR-Linked Bacterial Transposes to Insert Genes Into Human Cells (2d)
• Illumina Sues Element Biosciences, Alleging Infringement of Flow Cell, Imaging Patents (2d)
• StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via MA (2d)
• Malaria Turns Down Genes to Evade Immunity, Enable Chronic Infection (4d)
• The Future of Biomanufacturing: AI-Driven Cell Line Development and Bioprocess Design (4d)
• 3PBIOVIAN Introduces Two Platforms for AAV and pDNA Manufacturing (4d)
• Biotech and Beignets: The News from Day One of ASGCT (5d)

• Sixteen Years With Leukemia Taught Me to Savor Life (1h)
• Finding Meaning After an Acute Myeloid Leukemia Diagnosis (17h)
• Early Arterial Thrombosis May Signal Future Cancer Risk (18h)
• What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer? (19h)
• The Unnamed Nurse who Saved My Life During Breast Cancer (21h)
• Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases (22h)
• Prostate Cancer Treatment Options: Common Questions in Focal Therapy, Surgery (23h)
• With Cancer in Remission, What Is the New Normal for Patients? (1d)
• Younger Patients With Lung Cancer Often Have Targetable Biomarkers (1d)
• Facing Cancer as an AYA and Navigating Fertility Preservation Choices (1d)
• What Patients Should Know About a Melanoma Diagnosis (1d)
• Reflecting on my Son's Graduation as a Previvor (1d)
• Answers to Frequently Asked Questions About Prostate Cancer Risk, Treatment (2d)
• First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma (2d)
• Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma (2d)
• Fatigue, Sleep and Urinary Symptoms Affect Cognition in Prostate Cancer (2d)
• Providing Care and Listening With Compassion During Cancer (3d)
• Tagrisso Therapy Elicits Wave of New Therapeutic Approaches in NSCLC (3d)
• Cancer Didn’t Break Me; It Revealed My Strength (4d)
• EPA Deregulation Means More Air Pollution and More Cancer Deaths (4d)

Contract Pharma*

• IDT Biologika Enters CMDO Partnership to Accelerate Global Growth (14m)
• Waters Acquires Halo Labs, Expands Biologic Analysis Portfolio (28m)
• Antengene & MSD Enter into a Global Clinical Collaboration (28m)
• Regeneron in Deal to Acquire 23andMe for $256M (21h)
• Astoriom Expands Sample Stability Storage Services (22h)
• Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials (22h)
• NextCell, Fujifilm Irvine Scientific Enter Strategic Pact (22h)
• CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing (1d)
• CS Analytical Laboratory Opens Package Distribution Testing Service Expansion (1d)
• Shift Bioscience Announces Board and Advisor Appointments (1d)
• Zealand Pharma Appoints Chief Development Officer (1d)
• GC Biopharma Partners with Körber to Implement MES (2d)
• Cellino’s iPSC Manufacturing Technology Receives FDA AMT Designation (2d)
• FDA Approves Novavax COVID-19 Vaccine for High-Risk Adults (2d)
• Rznomics & Eli Lilly Enter Global Licensing Agreement (5d)
• BioMarin to Acquire Inozyme Pharma for $270M (5d)
• Novo Nordisk CEO to Step Down (5d)
• groninger Invests $14M in New Charlotte, NC Headquarters (5d)
• Abzena Establishes Scientific Advisory Board to Support Innovation Strategy (6d)
• FAMAR Group to Acquire Sterile Production Site in Homburg, Germany (6d)

• Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia (3h)
• FDA approves Amneal’s self-administered migraine drug Brekiya (1d)
• MHRA approves guselkumab for Crohn’s disease and ulcerative colitis (2d)
• Massalia Therapeutics launches to advance novel treatments for complex conditions (2d)
• AviadoBio opens UK trial for FTD gene therapy (6d)
• Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease (1w)
• Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment (1w)
• Rein Therapeutics initiates renew phase 2 trial for IPF treatment (1w)
• Apiary invests in life sciences marketing specialist performance-io (1w)
• Amgen’s Tepezza granted marketing authorisation in the UK (2w)
• iOnctura starts randomised phase 1/2 trial in lung cancer treatment (2w)
• MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d (2w)

• How Healthcare Organizations Can Maintain a Balanced Workforce Amid Staff Shortages and Burnout (1h)
• A Four-Part Roadmap for Responsible Prior Authorization (1h)
• How a New PE-Backed RCM Company Plans to Fix the ‘Transactional Bowels of US Healthcare’ (11h)
• 3 Health Investors Share Their Most Controversial Industry Takes (11h)
• How a Tiny Federal Agency Supports Innovation & Competitiveness in the Scientific Community (11h)
• Payments Simplified: The 4 Key Features of Modern Healthcare Payment Platforms (1d)
• The Changing Landscape of Ransomware: Why Healthcare Organizations Are Paying Less (1d)
• The Role of Consultants in Tackling Healthcare Expenses (1d)
• 23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts (1d)
• How One Company Aims to Save Lives with Its Smartwatch (1d)
• How One Startup Is Standing Out in the Crowded AI Scribe Market (1d)
• Why Agentic AI Is Not Quite Ready for Primetime in Healthcare (2d)
• 5 Companies That Offer Mobile IV Therapy With Experienced Nurses in NYC and Beyond (2d)
• The Influence of Digital Transformation and AI in the Future of Life Sciences (2d)
• How Smarter AI Strikes Back for Hospitals (2d)
• Sleep Apnea Relief in a Pill: Apnimed Drug’s Phase 3 Data Set Stage for FDA Submission (2d)
• Cleveland Clinic Digital Chief: Pick AI Problems That Clinicians Actually Care About (2d)
• Alzheimer’s Disease Now Has Its First FDA-Cleared Blood Test (3d)
• Why WeightWatchers Filed for Bankruptcy (3d)
• Connected Care, Shared Goals: Designing Whole-Person Care for Complex Patient Populations (3d)

• Editorial: Venture capital still likes cleantech (22h)
• A guide to navigating AI chemistry hype (22h)
• Federal policy changes spell turmoil for biopharma (1d)
• Global pandemic treaty nears adoption, but key obstacle remains (1d)
• ACS puts the spotlight on chemical technical professionals (2d)
• Comment: Why attend ACS Fall 2025? (2d)
• Mercury emissions are falling (2d)
• Flu virus transcription caught in the act (4d)
• AI start-up raises $11 million to make drug formulations better (4d)
• A baby gets the world’s first personalized CRISPR therapy (4d)
• UN chemicals meeting bans chlorpyrifos and 2 other pollutants, with caveats (4d)
• Researchers use electrochemistry to read data stored in molecules (5d)
• Denka closes neoprene plant criticized for harmful emissions (5d)
• Russia honors chemist who was suspended in Spain (5d)
• Electrochemist wins 2025 Dreyfus Prize (5d)
• Chemistry in Pictures: Color control (5d)
• Tell us: Are you a US-based researcher who’s tempted to move abroad? (5d)
• EPA to delay limits on PFAS in drinking water (6d)
• Hydrogel helps coral find new home (6d)
• 8 agencies to terminate $450 million in grants to Harvard (6d)

The Pharma Letter*

• ReproNovo raises $65 million in Series A financing (40m)
• vTv resumes Phase III oral T1D drug study (1h)
• Protagenic Therapeutics and Phytanix merge in all stock deal (1h)
• Juvenescence raises $76 million in first-close of Series B-1 round (2h)
• SparX teams with Mitsubishi Tanabe on novel ADC project (3h)
• PureTech’s deupirfenidone shows strong and durable efficacy (3h)
• Tourmaline shares waver as investors mull mid-stage pacibekitug data (3h)
• Tubulis achieves key milestone in BMS deal (4h)
• J&J presents long-term Opsynvi findings at ATS (4h)
• SK bio wins Korean Supreme Court backing in Pfizer patent battle (5h)
• FDA advisers back Darzalex, raise concerns over Columvi trial (5h)
• SK wins Korean Supreme Court backing in Pfizer patent battle (5h)
• MHRA launches new consultation on real-world clinical trials data (5h)
• Grünenthal appoints Maren Thurow to lead global comms (22h)
• HHS, CMS set Most-Favored-Nation pricing targets (23h)
• Australia’s digital health sector growing as global funding surges (23h)
• CEO among 25% of staff out the door at cash-strapped Prime (23h)
• Apnimed touts Phase III success for first-ever sleep apnea pill (1d)
• BioNTech expands partnership with UK govt, pledging £1 billion investment (1d)
• New $35 million partnership to advance blood disorder therapies (1d)

• FDA's Project Optimus Drives Increased Dose Optimization in Early Trials (57m)
• Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer (1h)
• CABINET Trial: Results (2h)
• CYTO-PV Trial Insights: Optimizing Hematocrit Targets and Thrombosis Prevention in Polycythemia Vera (2h)
• CABINET Trial: Study Design and Patient Population (2h)
• Comparative Analysis of Major Polycythemia Vera Clinical Trials: PROUD-PV, MAJIC-PV, RESPONSE, and CYTO-PV (2h)
• CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL (17h)
• ODAC Votes Daratumumab Benefits Smoldering MM (17h)
• Unmet Needs and Therapy Modifications Relevant in the CRC Landscape (19h)
• Myeloma Research Sees Transformation Following ODAC Support For MRD End Point (20h)
• The Importance of Global Collaboration in Oncology: Li's View (21h)
• FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting (21h)
• 2025 ASCO Annual Meeting: The Show and After Show (22h)
• ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL (22h)
• AI Predicts Prostate Cancer Prognosis Fairly Across Races (22h)
• Clinical Trial Awareness Day: Progress in Brain Cancer Research (23h)
• Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma (1d)
• Dermatological Complications of JAK Inhibitors: Monitoring and Management (1d)
• Persistent Challenges in Myelofibrosis Management: Unmet Needs (1d)
• Optimizing Anemia Care with Targeted Therapies for Low-Risk MDS (1d)

• EU to reduce companies' administrative costs by EUR 400m (1h)
• Fruergaard's exit leaves many questions: Speculation about cause, power struggle and US problems (2h)
• US health clinic Calibrate changes management (3h)
• Demant surpasses Novo Nordisk on list of Europe's best employers (4h)
• Genmab drug gets support from US authorities (6h)
• Trump shows first figures on decreed drug price cuts (7h)
• Zealand Pharma appoints new development chief with experience from Novo Nordisk and FDA (1d)
• China will provide extra support to WHO (1d)
• Regeneron acquires US biotech firm (1d)
• Over 100 countries vote for global pandemic agreement (1d)
• Pfizer licenses 3SBio cancer drug for record USD 1.25bn (1d)
• Novo Nordisk needs a new CEO: Headhunter gives three bids for Fruergaard's replacement (2d)
• China becoming largest contributor to WHO: "Life goes on without the Americans" (2d)
• FDA approves blood test for diagnosing Alzheimer's (2d)
• Foundation behind Eli Lilly is now the largest in the US (2d)
• Novo Nordisk should consider finding CEO in the US, analysts say (2d)
• Bavarian Nordic's chikungunya vaccine receives final US recommendation (2d)
• Novo Nordisk Foundation initiated Fruergaard's exit: "The timing is right" (5d)
• Lars Fruergaard Jørgensen steps down as CEO of Novo Nordisk (5d)
• Uncertainty sparked series of Q1 guidance downgrades among major life science companies (5d)

• Autoimmune Disease, Transformed? (19h)
• Lose Your Crystalline Form and Go Amorphous (1d)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (5d)
• Obesity Without Metabolic Dysfunction? (6d)
• New Cell Therapy For Resistant Hodgkins Patients (1w)
• Escape From the Lysosome (1w)
• Heavy Water in Your NMR Experiments, And Elsewhere (2w)
• GIPR: Agonists and Antagonists Do the Same Thing, But How (2w)
• Mutant Proteins Classified (2w)
• The Continuing Crisis, Part XIV: The Trumpist Worldview (2w)
• Whole Lotta Snakin' Going On (2w)
• The GLP-1 Saga Continues, And How (3w)
• Defluorination is Happening Inside You Right Now (3w)
• Treating Orthopox Viruses - With What? (3w)
• The Continuing Crisis, Part XIII: Lasting Damage (3w)
• What's Going On In Water Droplets (4w)
• A New Glioblastoma Treatment (4w)
• Streptomycin For Metastatic Cancer (4w)
• The End of Disease (4w)
• You Can Probably Smell That Planet From Here (1mo)

• US imposes limits on COVID-19 boosters and new jabs (1h)
• UK to start "world first" gonorrhoea vaccine programme (3h)
• Beckley's psychedelic med inches forward in depression (4h)
• UK trumpets £1bn investment plan from BioNTech (5h)
• First details of Trump's most favoured nation plan emerge (5h)
• O'Shaughnessy says UK clinical trials sector is on the mend (1d)
• Imec showcases ingestible sensor for gut studies (1d)
• UK's long-term R&D investment policy welcomed (1d)
• Pfizer snaps up PD-1/VEGF drug from China's 3SBio (1d)
• Regeneron swoops on genetic testing firm 23andMe (2d)
• Japan follows UK in GSK's comeback tour for Blenrep (2d)
• Partner of ex-Theranos CEO raising cash for testing start-up (2d)
• BioMarin starts rebuilding after its downsizing spree (2d)
• FDA finally okays Novavax's COVID-19 jab, with restrictions (2d)

• In Focus report: Cell therapy and opportunities for new medicines (56m)
• BioNTech commits to up to £1 billion investment in the UK (2h)
• Weight loss with muscle preservation for novel small molecule (4h)
• Whitepaper: Transforming cardiac safety testing (5h)
• VOLTA Scanner illuminates cardiac safety testing (5h)
• Cell therapy (beyond CAR-T) and opportunities for new medicines (6h)
• Meet the Researcher: Duncan McHale, Persica Pharmaceuticals (6h)
• Webinar: Where are the developments in cancer research? (6h)
• We need international partnerships to get new cancer drugs into the clinic (1d)
• Gene-based vaccine shows promise in early-stage trial (1d)
• First patient receives personalised CRISPR gene editing therapy (1d)
• First patients dosed in final cohort of Phase Ib Parkinson’s disease trial (1d)
• Tipping point in Huntington’s disease research (1d)
• Webinar: Rapid, comprehensive AAV genomic profiling made simple (1d)
• Novel GPR119 agonist shows promise in treating MASH and Type 2 diabetes (2d)
• More efficient next-gen obesity clinical trials needed, says survey (2d)
• SMC okays Pedmarqsi to prevent cisplatin-induced hearing loss (2d)
• New DDW Highlights podcast: 19 May 2025 (2d)
• DDW Highlights: 19 May 2025 (2d)
• GSK buys drug with potential to reverse liver fibrosis (2d)

Google News Biotech

• Sichuan Kelun-Biotech Announces 2025 AGM Agenda - TipRanks (17m)
• In Biotech’s ‘Moribund’ Market, What Does It Take to Survive? - BioSpace (52m)
• The genomics layoff wave in the US: What is happening and why - Labiotech.eu (57m)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - BioSpace (57m)
• Webinar: Are We There Yet? Surviving and Thriving in the Never-ending Biotech Downturn - BioSpace (1h)
• Dividing the Equity Pie: Biotech Startup Realities with Dr. Jahanara Ali - Lexology (1h)
• Lilly’s former small molecule head makes the leap to a rising biotech in obesity - Pharma Voice (2h)
• RBC downgrades Sartorius Stedim Biotech to “sector perform,” sets €240 target - Investing.com (2h)
• Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101 - The Manila Times (2h)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - ACCESS Newswire (2h)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - Morningstar (2h)
• Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101 - GlobeNewswire (2h)
• German biotech firm SenseUP closes €2.4M Seed round - Silicon Canals (3h)
• Purple Biotech Reports First Quarter 2025 Financial Results - The Manila Times (3h)
• Purple Biotech Reports First Quarter 2025 Financial Results - Yahoo Finance (3h)
• Bharat Biotech’s oral cholera vaccine Hillchol proves effective on year-old infants to adults - CNBC TV18 (3h)
• Genentech expands deal with molecular glue biotech Orionis for $105M upfront - Endpoints News (3h)
• tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member - PharmiWeb.com (4h)
• Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win - Fierce Biotech (4h)
• Bharat Biotech's cholera vaccine successfully completes Phase-III trials - The Economic Times (4h)